News

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR),…
Read More...

JURA Bio, a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced a research collaboration with Syena, a cell therapy…
Read More...

Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced an exclusive…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental new drug…
Read More...

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the…
Read More...

BeiGene, Ltd. announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab). “We are…
Read More...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and Astex Pharmaceuticals, Inc. (Astex) announce that the European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for LITFULO (ritlecitinib) to treat adults and adolescents 12 years of age and older with…
Read More...

BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for…
Read More...

Astellas Pharma Inc. announced its intention to submit a planning application to build a new state-of-the-art facility, at an approximate cost of €330 million in Tralee, Co. Kerry.…
Read More...

Charles River Laboratories International, Inc. and Related Sciences, a data science-driven drug discovery firm, announced a multi-program collaboration agreement to apply Logica™ across…
Read More...

Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of…
Read More...

AbCellera announced that it has entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology. “We are excited to partner with Incyte,…
Read More...

Vaxess Technologies, Inc, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, announced an additional $9 million in venture capital…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC)…
Read More...

Dewpoint Therapeutics and Chemify announced a partnership to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify's programmable chemistry…
Read More...

Sandoz announced that it has entered into a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz with the exclusive rights to commercialize…
Read More...

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for…
Read More...

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, announce a multi-target collaboration to develop…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery…
Read More...